Akrivia Biosciences Secures Pre-Seed Funding to Advance Precision Cancer Diagnostics

The funds will support the startup’s efforts to advance its groundbreaking work in cancer diagnostics, particularly in developing a multi-omics approach to precision medicine.

Akrivia Biosciences, a Mumbai-based deep tech startup in oncology precision diagnostics, has successfully secured pre-seed funding through Compulsory Convertible Debentures (CCDs) from JITO Incubation and Innovation Foundation (JIIF) and Rebalance Angels.

The funds will support the startup’s efforts to advance its groundbreaking work in cancer diagnostics, particularly in developing a multi-omics approach to precision medicine.

Additionally, the funding will be used for conducting Proof of Concept trials, building an internal research and development (R&D) team, and publishing scientific materials that validate Akrivia's innovative advancements in oncology.

A Multi-Omics Approach to Precision Medicine

Akrivia’s core innovation lies in its next-generation molecular subtyping tests, which employ a multi-omics approach to provide oncologists with comprehensive data for personalized cancer therapy.

The new diagnostic technology significantly departs from traditional one-size-fits-all treatments, offering a more targeted and individualized approach to cancer care.

Sagar Gosalia, Chief Operating Officer of JIIF, expressed confidence in Akrivia’s potential. “The world is recognizing the significance of precision medicine, which aims to provide the right cancer treatment to the right patient at the right time based on their unique molecular makeup. Akrivia Biosciences is bringing a multi-omics-based next-generation precision treatment solution that can transform cancer treatment strategies from a one-size-fits-all approach to precision medicine in its truest sense,” Gosalia said.

He added, “Our investment in Akrivia Biosciences aligns with our commitment to backing deeptech ventures that address critical healthcare challenges. Akrivia’s work in oncology precision diagnostics has the potential to redefine cancer treatment by enabling targeted, effective, and personalized therapies.”

Akrivia was founded based on a significant breakthrough made by Dr Amit Gupta, co-founder of the company, while analyzing cancer genomic data. His research has led to a deeper understanding of tumor biology, which impacts disease progression and treatment response. The research, validated by studies involving approximately 8,000 cancer patients over four years, forms the foundation of Akrivia’s approach to precision oncology.

Dr Amit Gupta explained, “Our tests are designed to go beyond conventional genetic panels. They provide oncologists with actionable insights, including long-term risk assessment of cancer recurrence and selection of the most effective targeted therapies for individual patients.”